2011
DOI: 10.1016/j.pupt.2011.03.001
|View full text |Cite
|
Sign up to set email alerts
|

Reevaluation of the efficacy and safety of the neutrophil elastase inhibitor, Sivelestat, for the treatment of acute lung injury associated with systemic inflammatory response syndrome; a phase IV study

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

2
116
1
1

Year Published

2012
2012
2022
2022

Publication Types

Select...
10

Relationship

0
10

Authors

Journals

citations
Cited by 107 publications
(126 citation statements)
references
References 26 publications
2
116
1
1
Order By: Relevance
“…Neutrophil elastase is a strong mediator of adult respiratory distress syndrome (ARDS), because neutrophil elastase is elevated in the sera and lung tissue of patients with ARDS [28][29][30][31]. There has been some evidence that a neutrophil elastase inhibitor is effective for the treatment of ARDS [32,33]. Since none of the present patients showed evidence of ARDS, the elevated levels of neutrophil elastase might reflect the pathological process of IE itself.…”
Section: Discussionmentioning
confidence: 87%
“…Neutrophil elastase is a strong mediator of adult respiratory distress syndrome (ARDS), because neutrophil elastase is elevated in the sera and lung tissue of patients with ARDS [28][29][30][31]. There has been some evidence that a neutrophil elastase inhibitor is effective for the treatment of ARDS [32,33]. Since none of the present patients showed evidence of ARDS, the elevated levels of neutrophil elastase might reflect the pathological process of IE itself.…”
Section: Discussionmentioning
confidence: 87%
“…oxygenation, multiple organ dysfunction score, and ventilator-weaning rate. [30][31][32][33] However, the STRIVE study, a clinical trial in ALI patients requiring mechanical ventilation, failed to demonstrate the efficacy of sivelestat. 34 The discrepancy might be due to differences in the severity of lung injury in the patients.…”
Section: Discussionmentioning
confidence: 99%
“…Sivelestat is a selective NE inhibitor and has been shown to be effective clinically in mitigating the effect of systemic inflammatory response in patients with acute lung injury. 25 PDT-treated tumors that received Sivelestat via intratumor injection were assayed for NE680 fluorescence, and the levels were compared to those obtained from unirradiated and irradiated tumors in the absence of Sivelestat. Figure 5 Sivelestat groups for both SCC VII and EMT6 tumors were not different at the P ¼ 0.1 significance level.…”
Section: Resultsmentioning
confidence: 99%